TreatSMA

Trials for the new antisense oligonucleotide drug by Biogen.

Published:

Updated:

Trials are taking place for the new antisense oligonucleotide drug by Biogen.

Similar to Spinraza, but believed to have a better stability in the human body. This means larger dose can be administered through spinal tap at longer intervals compared to Spinraza. We believe they are aiming for every 180 days but yet to be confirmed.

As this is a new drug the first stage will be to understand safety and how the drug actually behaves. So smaller doses will be given to start with and they will continue to increase it until they find a maximum safe dose.

This trial will be aimed at healthy people or those on gene therapy.

TreatSMA have contacted Biogen for more information.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more